Related Experiment Video
Updated: May 5, 2026

Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study
Stanley Xu1, Lina S Sy1, Vennis Hong1
1Department of Research & Evaluation, Southern California Permanente Medical Group, Pasadena, CA, United States.
Insights
Bivalent COVID-19 vaccination did not increase ischemic stroke risk overall. A potential increased risk was observed within 42 days for younger individuals receiving both Pfizer-BioNTech and flu vaccines, warranting further study.
Area of Science:
- Epidemiology
- Vaccinology
- Neurology
Background:
- The association between bivalent COVID-19 vaccines and ischemic stroke risk is not fully understood.
- Existing studies have yielded uncertain conclusions regarding this potential link.
Purpose of the Study:
- To assess the risk of ischemic stroke following bivalent COVID-19 vaccination during the 2022-2023 season.
- Evaluate potential associations in specific subgroups and with coadministered vaccines.
Main Methods:
- A self-controlled case series study design was employed.
- Utilized electronic health records for ischemic stroke identification (ICD-10 codes).
- Analyzed risk intervals of 1-21 and 1-42 days post-vaccination using conditional Poisson regression.
Main Results:
- No increased ischemic stroke risk was found within 21 days for either vaccine.
- An elevated risk was noted within 42 days for individuals under 65 receiving Pfizer-BioNTech and influenza vaccines concurrently.
- Subgroup analyses revealed potential elevated risks in specific populations, though often not statistically significant after chart review.
Conclusions:
- The study found no statistically significant increase in ischemic stroke risk associated with bivalent COVID-19 vaccination overall.
- Further investigation is needed for specific subgroups, particularly younger individuals receiving concurrent influenza vaccination and those with prior SARS-CoV-2 infection.
- Highlights the importance of ongoing vaccine safety surveillance, including for monovalent vaccines in the subsequent season.
Background:
The potential association between bivalent COVID-19 vaccination and ischemic stroke remains uncertain, despite several studies conducted thus far.
Objective:
This study aimed to evaluate the risk of ischemic stroke following bivalent COVID-19 vaccination during the 2022-2023 season.
Methods:
A self-controlled case series study was conducted among members aged 12 years and older who experienced ischemic stroke between September 1, 2022, and March 31, 2023, in a large health care system. Ischemic strokes were identified using International Classification of Diseases, Tenth Revision codes in emergency departments and inpatient settings. Exposures were Pfizer-BioNTech or Moderna bivalent COVID-19 vaccination. Risk intervals were prespecified as 1-21 days and 1-42 days after bivalent vaccination; all non-risk-interval person-time served as the control interval. The incidence of ischemic stroke was compared in the risk interval and control interval using conditional Poisson regression. We conducted overall and subgroup analyses by age, history of SARS-CoV-2 infection, and coadministration of influenza vaccine. When an elevated risk was detected, we performed a chart review of ischemic strokes and analyzed the risk of chart-confirmed ischemic stroke.
Results:
With 4933 ischemic stroke events, we found no increased risk within the 21-day risk interval for the 2 vaccines and by subgroups. However, risk of ischemic stroke was elevated within the 42-day risk interval among individuals aged younger than 65 years with coadministration of Pfizer-BioNTech bivalent and influenza vaccines on the same day; the relative incidence (RI) was 2.13 (95% CI 1.01-4.46). Among those who also had a history of SARS-CoV-2 infection, the RI was 3.94 (95% CI 1.10-14.16). After chart review, the RIs were 2.34 (95% CI 0.97-5.65) and 4.27 (95% CI 0.97-18.85), respectively. Among individuals aged younger than 65 years who received Moderna bivalent vaccine and had a history of SARS-CoV-2 infection, the RI was 2.62 (95% CI 1.13-6.03) before chart review and 2.24 (95% CI 0.78-6.47) after chart review. Stratified analyses by sex did not show a significantly increased risk of ischemic stroke after bivalent vaccination.
Conclusions:
While the point estimate for the risk of chart-confirmed ischemic stroke was elevated in a risk interval of 1-42 days among individuals younger than 65 years with coadministration of Pfizer-BioNTech bivalent and influenza vaccines on the same day and among individuals younger than 65 years who received Moderna bivalent vaccine and had a history of SARS-CoV-2 infection, the risk was not statistically significant. The potential association between bivalent vaccination and ischemic stroke in the 1-42-day analysis warrants further investigation among individuals younger than 65 years with influenza vaccine coadministration and prior SARS-CoV-2 infection. Furthermore, the findings on ischemic stroke risk after bivalent COVID-19 vaccination underscore the need to evaluate monovalent COVID-19 vaccine safety during the 2023-2024 season.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

